Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556683 · ClinicalTrials.gov registry record · NA
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
A NA study of Moderate to Severe Asthma, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03556683: Completed NA study of Moderate to Severe Asthma, sponsored by University of North Carolina, Chapel Hill.
NCT03556683 is a NA study of Moderate to Severe Asthma that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants, below the 787-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03556683, a NA study of Moderate to Severe Asthma, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
Primary Outcome
This outcome was the primary outcome maintained across the entire study (all cohorts). Smaller cohorts also examined the effect of 7% HS on MCC 4 hours after inhalation (Cohort 1), the effect of 3% HS on MCC immediate inhalation (Cohort 2), and the effect of albuterol alone on MCC (Cohort 3).
Conditions Studied
Interventions
- DEVICE 3% Hypertonic Saline
- DEVICE 7% Hypertonic Saline
- DRUG Salbutamol
Study Locations (1)
North Carolina
- Center for Environmental Medicine, Asthma and Lung Biology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2024-06-06 |
| Phase | NA |
What the finished NCT03556683 record still lists
NCT03556683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 787-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Moderate to Severe Asthma appearing as the primary indexed condition, and to 3 interventions - of which 3% Hypertonic Saline is the first listed.
NCT03556683 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03556683 about?
NCT03556683 is a clinical study titled "Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics". Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
What is the current status of trial NCT03556683?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-10-01. Estimated completion is 2024-06-06.
What conditions does trial NCT03556683 study?
This clinical trial studies the following conditions: Moderate to Severe Asthma.
What interventions are being tested in trial NCT03556683?
The interventions under investigation include: 3% Hypertonic Saline (DEVICE), 7% Hypertonic Saline (DEVICE), Salbutamol (DRUG).
Who is sponsoring clinical trial NCT03556683?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03556683 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI